Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600436'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 10.65 Med: 17.93 Max: 21.74
Current: 10.65
During the past 13 years, Zhangzhou Pientzehuang Pharmaceutical Co's highest Return-on-Tangible-Asset was 21.74%. The lowest was 10.65%. And the median was 17.93%.
SHSE:600436's Return-on-Tangible-Asset is ranked better than 79.42% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 3.015
vs SHSE:600436: 10.65
Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Zhangzhou Pientzehuang Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Zhangzhou Pientzehuang Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhangzhou Pientzehuang Pharmaceutical Co Return-on-Tangible-Asset Chart
Zhangzhou Pientzehuang Pharmaceutical Co Annual Data
SHSE:600436 vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Zhangzhou Pientzehuang Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhangzhou Pientzehuang Pharmaceutical Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhangzhou Pientzehuang Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Zhangzhou Pientzehuang Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 16.80% mean?
Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) has a Return-on-Tangible-Asset of 16.80% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors. This is near median its historical median of 17.93. Over the past decade, Zhangzhou Pientzehuang Pharmaceutical Co's Return-on-Tangible-Asset has ranged from 10.65 to 21.74. According to the industry distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #207 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 20.6%.
Is Zhangzhou Pientzehuang Pharmaceutical Co's Return-on-Tangible-Asset too high?
Zhangzhou Pientzehuang Pharmaceutical Co's current Return-on-Tangible-Asset of 16.80% is near median its 10-year median of 17.93. Over the past 10 years, this metric has ranged from a low of 10.65 to a high of 21.74. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.02. Zhangzhou Pientzehuang Pharmaceutical Co's value of 16.80% is 457.2% above this industry median. Based on the distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #207 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhangzhou Pientzehuang Pharmaceutical Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhangzhou Pientzehuang Pharmaceutical Co's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #207 out of 1006 companies for Return-on-Tangible-Asset. This places Zhangzhou Pientzehuang Pharmaceutical Co in the top 21% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.02. Zhangzhou Pientzehuang Pharmaceutical Co's value of 16.80% is 457.2% above this benchmark. Historically, Zhangzhou Pientzehuang Pharmaceutical Co's own Return-on-Tangible-Asset has ranged from 10.65 to 21.74 over the past decade. While the company's 10-year median is 17.93 vs. the industry median of 3.02, Zhangzhou Pientzehuang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.02, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhangzhou Pientzehuang Pharmaceutical Co's current Return-on-Tangible-Asset of 16.80% is 457.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhangzhou Pientzehuang Pharmaceutical Co's current Return-on-Tangible-Asset is 16.80%, which is near median its own 10-year median of 17.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhangzhou Pientzehuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥173.97, compared to a current price of ¥128.76 — trading 26% below its estimated fair value. The current Return-on-Tangible-Asset is 16.80%, which is near median its 10-year median of 17.93 and 457.2% above the Drug Manufacturers industry median of 3.02. Zhangzhou Pientzehuang Pharmaceutical Co's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436), the current Return-on-Tangible-Asset is 16.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) Overvalued in 2026?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥128.76 is trading 26% below its estimated GF Value™ of ¥173.97.
GuruFocus considers Zhangzhou Pientzehuang Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600436:
Return-on-Tangible-Asset: 16.80% (near median its 10-year median of 17.93)
GF Value™: ¥173.97 vs. price of ¥128.76 (26% below fair value)
Industry Position: 457.2% above the Drug Manufacturers median (#207 of 1006)
No single metric tells the full story. See the SHSE:600436 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd produces and sells Chinese medicines. The company's product categories include tablets, hard capsules, granules, pills (water pills, honey pills), syrups, tinctures (including external use), ointments, lozenges, decoctions, Chinese herbal medicine slices (including direct oral slices) (clean preparation); production of candy products (candy), health food products; and production of beverages (solid beverages).
82GF Score
Get the complete analysis for SHSE:600436
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600436 has been successfully added to your 
